Abstract OT-18-01: The metastatic breast cancer project: Generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research

2021 ◽  
Author(s):  
Nikhil Wagle ◽  
Corrie Painter ◽  
Elana Anastasio ◽  
Michael Dunphy ◽  
Mary McGillicuddy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Genomic Landscape ◽  
Cancer Project

Abstract PD8-01: The metastatic breast cancer project: Generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research

2020 ◽  
Author(s):  
Nikhil Wagle ◽  
Corrie Painter ◽  
Elana Anastasio ◽  
Michael Dunphy ◽  
Mary McGillicuddy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Genomic Landscape ◽  
Cancer Project

scholarly journals Introducing the Metastatic Breast Cancer Project: a novel patient-partnered initiative to accelerate understanding of MBC

ESMO Open ◽  
2018 ◽  
Vol 3 (7) ◽  
pp. e000452 ◽  
Author(s):  
Marina Parry
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Link Type ◽  
Cancer Project

Click here to listen to the Podcast

Abstract 5371: The Metastatic Breast Cancer Project: Partnering with patients to accelerate progress in cancer research

2018 ◽  
Author(s):  
Nikhil Wagle ◽  
Corrie Painter ◽  
Elana Anastasio ◽  
Michael Dunphy ◽  
Mary McGillicuddy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Research ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cancer Project

Abstract GS1-07: The genomic landscape of 501 metastatic breast cancer patients

2019 ◽  
Author(s):  
L Angus ◽  
SM Wilting ◽  
J van Riet ◽  
M Smid ◽  
TG Steenbruggen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Genomic Landscape

Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 1059-1059
Author(s):  
Huiping Li ◽  
Andrew A. Davis ◽  
Xiao-ran Liu ◽  
Feng Xie ◽  
Xin-Yu Gui ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
The United States ◽  
Chinese Patients ◽  
Hormone Receptor Positive ◽  
Genomic Landscape ◽  
The Us ◽  
Chinese Cohort

1059 Background: Metastatic breast cancer (MBC) is a heterogeneous disease associated with known somatic mutations of variable biological value in different subtypes. Furthermore, the clinical evolution of the disease demonstrates clonal evolution resulting in disease resistance more accurately detected using blood-based sequencing. Few studies have explored differences in genomic features of tumors across populations. Here, we performed circulating tumor DNA (ctDNA) sequencing to compare the genomic landscape of patients with hormone-receptor positive MBC at time of first recurrence or de-novo metastatic diagnosis in the United States (US) and China. Methods: Twenty-three US patients from Northwestern University and 65 Chinese patients from Peking University had ctDNA sequencing from plasma performed using the harmonized CLIA-certified, 152-gene PredicineCARE assay in laboratories in the US and China, respectively. The data analysis was conducted in China. Institutional Review Boards at each site approved the study. Fisher’s exact test was performed to compare mutational frequencies across populations. Results: Median age of patients at MBC diagnosis was 51 in the US cohort and 55 in the Chinese cohort. 87% of US patients and 82% of Chinese patients had received prior therapy for primary breast cancer, including endocrine therapy. Mutations were detected in 17 of 23 (74%) US patients and 59 of 65 (91%) Chinese patients. CNAs were observed in 57% of US patients and 58% of Chinese patients. The most common mutations detected in US patients were TP53 (26%), PIK3CA (22%), AKT1 (22%), CDH1 (17%), PTEN (13%), and ESR1 (9%) vs. PIK3CA (46%), TP53 (35%), ESR1 (12%), and BRCA2 (11%) in Chinese patients. Frequency of AKT1 and CDH1 mutations were significantly higher in the US population (P < 0.05), while PIK3CA mutations were higher in the Chinese population (P < 0.05). CNA gains in CCND3 and CDK4 were significantly higher in the US cohort, and FGFR1 was significantly more common in the Chinese cohort (all P < 0.05). Conclusions: To our knowledge, this is a first cross-regional comparison study in HR+ MBC patients in the US and China using a harmonized cfDNA NGS platform. At a population level, there were notable differences observed in somatic variants in two cohorts. Future sequencing efforts and clinical trials should include patients of diverse ethnic backgrounds to explore the impact of differences in genomic landscape on probability of benefit from treatments. A larger validation cohort is required to confirm these findings.

Abstract P1-05-13: The metastatic breast cancer project: Translational genomics through direct patient engagement

2017 ◽  
Author(s):  
CA Painter ◽  
E Anastasio ◽  
M Krevalin ◽  
D Kim ◽  
K Larken ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Patient Engagement ◽  
Metastatic Breast ◽  
Translational Genomics ◽  
Cancer Project

Abstract PD8-04: Evolutionary history and genomic landscape of metastatic breast cancer

2018 ◽  
Author(s):  
MR Paul ◽  
T-C Pan ◽  
D Pant ◽  
GK Belka ◽  
Y Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Evolutionary History ◽  
Metastatic Breast ◽  
Genomic Landscape
Sign in / Sign up

Export Citation Format

Share Document